Compare · SNCE vs SNOW
SNCE vs SNOW
Side-by-side comparison of Science 37 Holdings Inc. (SNCE) and Snowflake Inc. (SNOW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SNCE and SNOW operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- SNOW carries a market cap of $95.09B.
- SNOW has hit the wire 14 times in the past 4 weeks while SNCE has been quiet.
- SNOW has more recent analyst coverage (25 ratings vs 5 for SNCE).
- Company
- Science 37 Holdings Inc.
- Snowflake Inc.
- Price
- -
- -
- Market cap
- -
- $95.09B
- 1M return
- -
- -19.05%
- 1Y return
- -
- +1.81%
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2020
- News (4w)
- 0
- 14
- Recent ratings
- 5
- 25
Snowflake Inc.
Snowflake Inc. provides cloud-based data platform in the United States and internationally. The company's platform offers Data Cloud, an ecosystem that enables customers to consolidate data into a single source of truth to drive meaningful business insights, build data-driven applications, and share data. Its platform is used by various organizations of various sizes in a range of industries. The company was formerly known as Snowflake Computing, Inc. and changed its name to Snowflake Inc. in April 2019. Snowflake Inc. was incorporated in 2012 and is headquartered in San Mateo, California.
Latest SNCE
- Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
- Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
- Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
- Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
- Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
- Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
- Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
- Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
Latest SNOW
- Director Dageville Benoit gifted 16,668 shares and sold $14,617,500 worth of shares (50,000 units at $292.35) as part of a pre-agreed trading plan (SEC Form 4)
- EVP, Product Management Kleinerman Christian sold $3,060,100 worth of shares (10,000 units at $306.01) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 303,738 units (SEC Form 4)
- Snowflake CoCo and CoWork Power the Agentic Enterprise, Grounded in Governed Data and Built for Autonomous Action
- Snowflake Delivers the Foundation for Autonomous Data Engineering, Powering the Agentic Enterprise with Trusted, Live Data
- Snowflake Helps Enterprises Deploy AI Agents with Trusted Business Context and Built-In Controls
- USA Cycling Selects Snowflake to Accelerate Race Strategy on the Road to the LA28 Games
- Snowflake to Present at Upcoming Investor Conferences
- Snowflake to Announce Financial Results for the Third Quarter of Fiscal 2027 on December 2, 2026
- Oracle Expands Native AI and Data Services on OCI with Snowflake
- Director Dageville Benoit sold $16,087,000 worth of shares (50,000 units at $321.74) as part of a pre-agreed trading plan (SEC Form 4)